{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:37:27Z","timestamp":1783535847975,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jfma.2025.08.022","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T11:10:21Z","timestamp":1755947421000},"page":"1010-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expert consensus on clinical usefulness of M2BPGi for managing chronic liver diseases"],"prefix":"10.1016","volume":"124","author":[{"given":"Tai-Chung","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-7941","authenticated-orcid":false,"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0827-4503","authenticated-orcid":false,"given":"Chia-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwai-I","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-1901","authenticated-orcid":false,"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.08.022_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.08.022_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00535-017-1425-z","article-title":"Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis","volume":"53","author":"Shirabe","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib3","first-page":"1","article-title":"Comparing M2BPGi, APRI and FIB4 for liver fibrosis staging with histopathology in chronic hepatitis B","volume":"18","author":"Hsu","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2025.08.022_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220663","article-title":"Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients","volume":"14","author":"Yeh","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2025.08.022_bib5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/1751-2980.13140","article-title":"Diagnostic accuracy of mac-2-binding protein glycosylation isomer for diagnosing hepatitis B-related fibrosis: a meta-analysis","volume":"23","author":"Lian","year":"2022","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jfma.2025.08.022_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41424-018-0020-9","article-title":"Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection","volume":"9","author":"Mak","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hepr.12703","article-title":"Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naive chronic hepatitis B","volume":"47","author":"Ishii","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.08.022_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/liv.13188","article-title":"Serum WFA(+) -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection","volume":"37","author":"Zou","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2025.08.022_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S2468-1253(24)00089-X","article-title":"WHO 2024 hepatitis B guidelines: an opportunity to transform care","volume":"9","author":"Easterbrook","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.08.022_bib10","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.15006","article-title":"Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B","volume":"48","author":"Hsu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2025.08.022_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/hepr.12712","article-title":"Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"47","author":"Ichikawa","year":"2017","journal-title":"Hepatol Res : Off J Jpn Soc Hepatol"},{"key":"10.1016\/j.jfma.2025.08.022_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003328","article-title":"Use of Wisteria floribunda agglutinin-positive human Mac-2 binding protein in assessing risk of hepatocellular carcinoma due to hepatitis B virus","volume":"95","author":"Heo","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jfma.2025.08.022_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/liv.13341","article-title":"Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development","volume":"37","author":"Kim","year":"2017","journal-title":"Liver Int : Off J Intl Assoc Study Liver"},{"key":"10.1016\/j.jfma.2025.08.022_bib14","article-title":"Serum levels of M2BPGi as short-term predictors of hepatocellular carcinoma in untreated chronic hepatitis B patients","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.08.022_bib15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep4.1321","article-title":"Mac-2 binding protein glycosylation Isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection","volume":"3","author":"Jun","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jfma.2025.08.022_bib16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3748\/wjg.v25.i11.1398","article-title":"Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients","volume":"25","author":"Mak","year":"2019","journal-title":"World J Gastroenterol : WJG"},{"key":"10.1016\/j.jfma.2025.08.022_bib17","doi-asserted-by":"crossref","first-page":"47507","DOI":"10.18632\/oncotarget.17670","article-title":"Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment","volume":"8","author":"Cheung","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jfma.2025.08.022_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000504650","article-title":"Baseline Mac-2 binding protein glycosylation isomer level stratifies risks of hepatocellular carcinoma in chronic hepatitis B patients with oral antiviral therapy","volume":"9","author":"Tseng","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jfma.2025.08.022_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00535-017-1424-0","article-title":"High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues","volume":"53","author":"Shinkai","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib20","first-page":"589","article-title":"Serum Mac-2-Binding protein glycosylation isomer at virological remission predicts hepatocellular carcinoma and death in chronic hepatitis B-Related cirrhosis","volume":"221","author":"Su","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2025.08.022_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205063","article-title":"A Mac-2 binding protein glycosylation isomer-based risk model predicts hepatocellular carcinoma in HBV-related cirrhotic patients on antiviral therapy","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jfma.2025.08.022_bib22","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.62347\/DAGB7277","article-title":"Mac-2 binding protein glycosylation isomer at 5 years of antiviral therapy predict hepatocellular carcinoma and mortality beyond year 5 in chronic hepatitis B patients with cirrhosis","volume":"14","author":"Chen","year":"2024","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jfma.2025.08.022_bib23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s00535-017-1386-2","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B","volume":"53","author":"Kawaguchi","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/srep01065","article-title":"A serum \"sweet-doughnut\" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis","volume":"3","author":"Kuno","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.08.022_bib25","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/hep.27305","article-title":"Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients","volume":"60","author":"Yamasaki","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2025.08.022_bib26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.kjms.2017.05.017","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients","volume":"33","author":"Huang","year":"2017","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.08.022_bib27","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/SLA.0000000000001836","article-title":"Usefulness of Mac-2 binding protein glycosylation isomer for prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma","volume":"265","author":"Okuda","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.jfma.2025.08.022_bib28","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1111\/hepr.12466","article-title":"Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients","volume":"45","author":"Tamaki","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.08.022_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/apt.13431","article-title":"Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C","volume":"43","author":"Ura","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2025.08.022_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7090267","article-title":"Fibrosis staging using direct serum biomarkers is influenced by hepatitis activity grading in hepatitis C virus infection","volume":"7","author":"Fujita","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.jfma.2025.08.022_bib31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00535-024-02100-3","article-title":"Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation","volume":"59","author":"Uojima","year":"2024","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12112650","article-title":"Serum Mac-2 binding protein glycosylation isomer to predict the severity of hepatic fibrosis in patients with hepatitis C virus infection","volume":"12","author":"Liu","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.jfma.2025.08.022_bib33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12876-020-01459-w","article-title":"Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection","volume":"20","author":"Ueda","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12876-017-0618-5","article-title":"Accuracy of M2BPGi, compared with fibro Scan(R), in analysis of liver fibrosis in patients with hepatitis C","volume":"17","author":"Xu","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib35","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.3748\/wjg.v26.i21.2864","article-title":"M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals","volume":"26","author":"Saleh","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/hepr.13630","article-title":"Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals","volume":"51","author":"Chuaypen","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.08.022_bib37","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1111\/jgh.16680","article-title":"Serum Mac-2 binding protein glycosylation isomer dynamics in patients achieving sustained virologic response for hepatitis C virus","volume":"39","author":"Chang","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.08.022_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124517","article-title":"Post-treatment M2BPGi level and the rate of autotaxin reduction are predictive of hepatocellular carcinoma development after antiviral therapy in patients with chronic hepatitis C","volume":"21","author":"Takemura","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jfma.2025.08.022_bib39","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"Nagata","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.08.022_bib40","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/hepr.13233","article-title":"Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus","volume":"48","author":"Yasui","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.08.022_bib41","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00535-020-01715-6","article-title":"Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs","volume":"55","author":"Nakagawa","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129053","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response","volume":"10","author":"Sasaki","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2025.08.022_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103640","article-title":"Wisteria floribunda agglutinin-positive Mac-2 binding protein but not \u03b1-fetoprotein as a long-term hepatocellular carcinoma predictor","volume":"21","author":"Osawa","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jfma.2025.08.022_bib44","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1245\/s10434-021-11011-z","article-title":"Mac-2-Binding protein glycosylation isomer as a novel predictor of hepatocellular carcinoma recurrence in patients with hepatitis C virus eradication","volume":"29","author":"Yugawa","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jfma.2025.08.022_bib45","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/hepr.13412","article-title":"Preoperative Mac-2 binding protein glycosylation isomer level predicts postoperative ascites in patients with hepatic resection for hepatocellular carcinoma","volume":"49","author":"Ishii","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.08.022_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10030173","article-title":"Use of the serum Wisteria floribunda agglutinin-positive Mac2 binding protein as a marker of gastroesophageal varices and liver-related events in chronic hepatitis C patients","volume":"10","author":"Hayashi","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.jfma.2025.08.022_bib47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.aohep.2020.04.002","article-title":"Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients","volume":"19","author":"Kikukawa","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jfma.2025.08.022_bib48","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/hepr.12662","article-title":"Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.08.022_bib49","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis","volume":"13","author":"Alkhouri","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2025.08.022_bib50","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/jgh.14156","article-title":"Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease","volume":"33","author":"Ogawa","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.08.022_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46172-1","article-title":"Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease","volume":"9","author":"Tamaki","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.08.022_bib52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/kjm2.12474","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients","volume":"38","author":"Jang","year":"2022","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2025.08.022_bib53","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3343\/alm.2021.41.3.302","article-title":"Diagnostic efficacy of serum Mac-2 binding protein glycosylation Isomer and other markers for liver fibrosis in non-alcoholic fatty liver diseases","volume":"41","author":"Jang","year":"2021","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.jfma.2025.08.022_bib54","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.115400","article-title":"Serum Mac-2 binding protein glycosylation isomer (M2BPGi) can predict mild or significant liver fibrosis in non-alcoholic fatty liver disease","volume":"21","author":"Cheng","year":"2021","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jfma.2025.08.022_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277380","article-title":"Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis","volume":"17","author":"Kiyoaki","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2025.08.022_bib56","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ajg.2015.118","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2-Binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis","volume":"110","author":"Umemura","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib57","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hepr.12595","article-title":"Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-gamma-inducible protein-10 in primary biliary cirrhosis","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.08.022_bib58","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/hepr.12596","article-title":"Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.08.022_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013450","article-title":"Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis","volume":"97","author":"Migita","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.jfma.2025.08.022_bib60","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00383-018-4317-2","article-title":"Clinical implications of serum Mac-2-binding protein (M2BPGi) during regular follow-up of patients with biliary atresia","volume":"34","author":"Ueno","year":"2018","journal-title":"Pediatr Surg Int"},{"key":"10.1016\/j.jfma.2025.08.022_bib61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00535-016-1235-8","article-title":"Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia","volume":"52","author":"Yamada","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.08.022_bib62","first-page":"68","article-title":"M2BPGi correlated with immunological biomarkers and further stratified recurrence risk in patients with hepatocellular carcinoma","volume":"14","author":"Lee","year":"2025","journal-title":"Liver Cancer"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625004413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625004413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:03:58Z","timestamp":1761829438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625004413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0929664625004413"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.08.022","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert consensus on clinical usefulness of M2BPGi for managing chronic liver diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}